Erythropoiesis-stimulating agents versus RBC transfusion in MDS: Comparison of long-term outcomes

Future Oncology

Volumn 3, Issue 4, 2007, Pages 397-403

  Mundle, Suneel D ^a,b  

^a Ortho Biotech Products LP   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erythropoiesis stimulating agent; Erythropoietin; Hematopoietic growth factor; Leukemic transformation; Myelodysplastic syndrome; Red blood cell transfusion; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALLOIMMUNIZATION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DYSERYTHROPOIESIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; LEUKEMIA; LIVER TOXICITY; LONG TERM CARE; MALIGNANT TRANSFORMATION; META ANALYSIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY ANEMIA; RISK BENEFIT ANALYSIS; SEIZURE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANEMIA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMATINICS; HUMANS; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 34547856639     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.4.397     Document Type: Article

References (33)

1. Komrokji RS, Bennett JM: Evolving classificadons of the myelodysplastic syndromes. Curr. Opin. Hematol. 14, 98-105 (2007).
2. Steensma DP, Heptinstall KV, Johnson VM et al.: Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey. Leuk. Res. 31 (Suppl. 1), S106 (2007) (Abstract P123).
3. Oliva EN, Dimitrov BD, Benedetto F, Angelo AD, Nobile F: Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk. Res. 29, 1217-1219 (2005).
4. Jansen AJG, Essink-Bot ML, Beckers EAM, Hop WCJ, Scgipperus MR, van Rhenen DJ: Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br. J. Haematol. 121, 270-274 (2003).
5. Manolis AS, Tzeis S, Triantafyllou K et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5, 355-375 (2005).
6. Germing U, Strupp C, Kuendgen A et al.: Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91, 1596-1604 (2006).
7. Balducci L: Transfusion independence in patients with myelodysplastic syndromes: Impact on outcomes and quality of life. Cancer 106, 2087-2094 (2006).
8. Wallis JP, Wells AW, Matthews JN, Chapman CE: Long-term survival after blood-tranfusion: a population based study in the North of England. Transfusion 44, 1025-1032 (2004).
9. Malcovati L, Giovanni DP, Pascutto C et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23, 7594-7603 (2005).
10. Cazzola M, Malcovati L: Myelodysplastic syndromes coping with ineffective hematopoiesis. N. Engl. J. Med. 352, 536-538 (2005).
11. Malcovati L, Giovanni DP, Cazzola M: Predicting survival and leukemic evolution in patients with myelodysplastic syndromes. Haematologica 91, 158-1590 (2006).
12. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA: Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk. Res. 23, 953-959 (1999).
13. Heptinstall K: Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums. Leuk. Res. 31 (Suppl. 1), S107 (2007) (Abstract P124).
14. Takatoku M, Uchiyama T, Okamoto S et al.: Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/ mortality. Eur. J. Haematol. 78, 487-494, (2007).
15. Frytak JR, Henk HJ, de Castro CM, Halpern R. Nelson M: Cost of transfusion dependendcy among managed care patients with myelodysplastic syndromes. Leuk. Res. 31(Suppl. 1), S111 (2007) (Abstract P132).
16. Steensma DP, Bennett JM: The myelodysplastic syndromes- Diagnosis and Treatment. Mayo Clin. Proc. 81, 104-130 (2006).
17. Panini AD, Roussos C: Cytogenetic aspects of adult primary myelodysplastic syndromes: Clinical Implications. Cancer Lett. 235, 177-190 (2006).
18. Mundle SD: Advances in erythropoietic growth factor therapy for myelodysplastic syndromes. Expert Opin. Biol. Ther. 6, 1099-1104 (2006).
19. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106, 803-811 (2005).
20. Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR: Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 5, 323-327 (1992).
21. Tsabouri SE, Georgiou I, Katsaraki A, Bourantas KI: Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs. J. Exp. Clin. Cancer Res. 23, 417-424 (2004).
22. Aloe Spiriti MA, Latagliata R, Niscola P et al.: Impact of a new dosing regimen of epoetin α on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann. Hematol. 84, 167-176 (2005).
23. Musto P, Lanza F, Balleari E et al.: Darbepoetin α for the treatment of anemia in low-intermediate risk myelodysplastic syndromes. Br. J. Haematol. 128, 204-209 (2005).
24. Stasi R, Abruzzese E, Lanzetta. G, Terzoli E, Amadori S: Darbepoetin α for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann. Oncol. 16, 1921-1927 (2005).
25. Casadevall N, Durieux P, Dubois S et al.: Health, economic and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104, 321-327 (2004).
26. Golshayan AR, Jin T, Maciejewski J et al.: Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br. J. Haematol. 137, 125-132 (2007).
27. Jädersten M, Malcovati L, Dybedal I et al.: Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood 108, 158a (2006) (Abstract 521).
28. Wallvik J, Stenke L, Bernell P et al.: Serum erythmpoietin levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur. J. Haematol. 68, 180-186 (2002).
29. Miller KB, Kim HT, Greenberg P et al.: Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG trial (E1996). Blood 104, (2004) (Abstract 70).
30. Musto P, Giovanni S: Recombinant erythropoietin and survival in myelodysplastic syndromes. Blood 106, (2005) (Abstract 2539).
31. Park S, Grabar S, Kelaidi et al.: Has treatment with EPO ± G-CSF an impact on low-/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database. Leuk. Res. 31 (Suppl. 1), S113 (2007) (Abstract P135).
32. Italian Cooperative Group for rHuEpo in myelodysplastic syndromes: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br. Haematol. 103, 1070-1074 (1998).
33. Terpos E, Mougiou A, Kouraklis A et al.: Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a Phase II trial in 281 patients. Br. J. Haematol. 118, 174-180 (2002).